Gilead Sciences (GILD) Webpage traffic Statistics 2025

553,000 19.8%

1M 19.7% 3M 7.2%

Est. monthly webpage visitors.

Similar companies

Company		Webpage traffic
	Amgen AMGN	535,000 11.8%
	Catalyst Pharmaceuticals CPRX	8,000 22.7%
	Inovio Pharmaceuticals INO	8,000 17.9%
	Anavex Life Sciences AVXL	11,000 1.7%
	BridgeBio Pharma BBIO	27,000 29.1%

Month over Month

Est. monthly webpage visitors.

Sep 2025	553,000	19.7%
Aug 2025	462,000	13.2%
Jul 2025	532,000	3.1%
Jun 2025	516,000

How many visits gilead.com?

Gilead Sciences has an estimate of 553,000 visitors to gilead.com in September. This is up since August.

Analyzing Webpage traffic, how is Gilead Sciences performing compared to its industry peers?

Gilead Sciences underperforms its industry peers when it comes to Webpage traffic, ranking in the 10th percentile.

Why is it important to track website traffic for Gilead Sciences?

By staying updated on webpage traffic for Gilead Sciences, investors can gain valuable insights into the company's digital performance, customer engagement and acquisition, and overall effectiveness of its online presence. Higher traffic can indicate greater visibility and potential customer exposure and a lower or decreasing traffic can indicate challenges with retaining customers.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.